Hims & Hers Health (NYSE:HIMS – Get Rating) is set to release its earnings data after the market closes on Monday, May 8th. Analysts expect Hims & Hers Health to post earnings of ($0.04) per share for the quarter. Hims & Hers Health has set its FY 2023 guidance at EPS and its Q1 2023 guidance at EPS.Persons that are interested in registering for the company’s earnings conference call can do so using this link.
Hims & Hers Health (NYSE:HIMS – Get Rating) last issued its earnings results on Monday, February 27th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02. The business had revenue of $167.30 million for the quarter, compared to analyst estimates of $161.18 million. Hims & Hers Health had a negative net margin of 12.47% and a negative return on equity of 20.69%. The company’s quarterly revenue was up 97.5% compared to the same quarter last year. During the same period last year, the company posted ($0.11) earnings per share. On average, analysts expect Hims & Hers Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Hims & Hers Health Stock Up 0.4 %
Shares of HIMS stock opened at $11.59 on Monday. The firm has a market cap of $2.42 billion, a price-to-earnings ratio of -36.22 and a beta of 0.46. The company’s 50 day moving average is $10.08 and its 200 day moving average is $7.79. Hims & Hers Health has a 52-week low of $2.72 and a 52-week high of $12.23.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on the stock. Piper Sandler lifted their price objective on shares of Hims & Hers Health from $10.00 to $11.00 in a report on Wednesday, April 26th. Tigress Financial lifted their price objective on shares of Hims & Hers Health from $11.00 to $12.00 in a report on Tuesday, January 10th. Jefferies Financial Group raised shares of Hims & Hers Health from a “hold” rating to a “buy” rating and lifted their price objective for the company from $7.00 to $11.00 in a report on Thursday, February 9th. Citigroup lifted their price target on shares of Hims & Hers Health from $9.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, February 28th. Finally, Credit Suisse Group lifted their price target on shares of Hims & Hers Health from $8.00 to $14.00 and gave the stock an “outperform” rating in a report on Wednesday, March 1st. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, Hims & Hers Health currently has an average rating of “Moderate Buy” and an average target price of $11.77.
Insider Transactions at Hims & Hers Health
In other news, Director Alex Bard sold 500,000 shares of Hims & Hers Health stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $11.55, for a total transaction of $5,775,000.00. Following the completion of the sale, the director now directly owns 296,878 shares in the company, valued at $3,428,940.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Alex Bard sold 500,000 shares of Hims & Hers Health stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $11.55, for a total transaction of $5,775,000.00. Following the completion of the sale, the director now directly owns 296,878 shares in the company, valued at $3,428,940.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Soleil Boughton sold 50,000 shares of the business’s stock in a transaction on Tuesday, January 31st. The shares were sold at an average price of $8.14, for a total transaction of $407,000.00. Following the transaction, the insider now owns 237,089 shares of the company’s stock, valued at $1,929,904.46. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 739,721 shares of company stock worth $8,050,918. Company insiders own 35.22% of the company’s stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC lifted its position in Hims & Hers Health by 8.4% during the fourth quarter. Virtu Financial LLC now owns 18,441 shares of the company’s stock valued at $118,000 after purchasing an additional 1,430 shares during the period. Northern Trust Corp lifted its position in Hims & Hers Health by 1.3% during the first quarter. Northern Trust Corp now owns 253,307 shares of the company’s stock valued at $1,350,000 after purchasing an additional 3,226 shares during the period. Tower Research Capital LLC TRC lifted its position in Hims & Hers Health by 70.2% during the third quarter. Tower Research Capital LLC TRC now owns 9,538 shares of the company’s stock valued at $54,000 after purchasing an additional 3,933 shares during the period. Royal Bank of Canada raised its position in shares of Hims & Hers Health by 18.4% in the first quarter. Royal Bank of Canada now owns 26,523 shares of the company’s stock worth $140,000 after acquiring an additional 4,126 shares during the period. Finally, Point72 Middle East FZE acquired a new position in shares of Hims & Hers Health in the fourth quarter worth about $29,000. 45.60% of the stock is currently owned by institutional investors and hedge funds.
About Hims & Hers Health
Hims & Hers Health, Inc operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.